BUSINESS● LOW2h ago · Sep 25, 2026, 11:00 AM
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
CNBC · global
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESSnowWhy Dangote is investing 660 million dollars in a pipeline between Djibouti and EthiopiaJeune AfriqueBUSINESS20m agoBARK rallies as GNK evaluates potential acquisition offerSeeking Alpha Tech